肺纖維化生物標記市場規模、佔有率和成長分析：按生物標記類型、檢體類型、應用、最終用戶、技術和地區分類－2026-2033年產業預測

2024 年全球肺纖維化生物標記市場規模為 6.24 億美元，預計到 2033 年將從 2025 年的 7.0262 億美元成長到 18.1565 億美元，預測期（2026-2033 年）複合年成長率為 12.6%。

全球肺纖維化生物標記市場涵蓋了用於檢測和監測特發性肺纖維化及相關間質性肺部疾病的檢測和影像診斷技術。該市場的重要性體現在肺纖維化疾病的高死亡率和有限的治療選擇上，因此，對患者進行有效的抗纖維化治療分層至關重要。最初，該市場主要由靶向表面活性蛋白D的ELISA試劑盒主導，但近年來，次世代定序和蛋白質組學技術的進步催生了KL-6和基質金屬蛋白酶-7等新型生物標記。這些創新正在推動產品商業化，並促進業內合作。治療策略制定中對生物標記數據的依賴性日益增強，伴隨診斷的保險報銷範圍不斷擴大，以及對可靠治療反應標誌物的需求不斷成長，這些因素共同推動了投資和合作，顯著擴大了市場規模和潛力。

全球肺纖維化生物標記市場成長要素

對肺纖維化早期檢測的日益重視正在顯著推動全球生物標記市場的發展。臨床醫生能夠在不可逆的組織改變發生之前進行干預，這促使人們對能夠識別疾病早期階段的高靈敏度生物標記的需求不斷成長。醫療機構越來越注重疾病的預防管理，尋求能夠促進風險評估和個人化治療策略的先進診斷工具。這一發展趨勢為生物標記開發商創造了有利的環境，刺激了研發投入的增加，並推動了旨在早期治療性介入和改善患者預後的創新檢測方法的快速開發。

全球肺纖維化生物標記市場面臨的限制因素

肺纖維化生物標記檢測的普及受到醫療機構報銷體係不完善的限制。當保險公司提供的報銷範圍有限或根本不予報銷時，醫療服務提供者往往因擔心患者承擔費用而不願推薦先進的診斷檢測，從而造成經濟障礙。結果，這些檢測的使用率下降，進而降低市場需求，並阻礙製造商擴大生產或投資研發新檢測方法。最終，市場成長放緩，在缺乏報銷政策支持的地區，檢測普及率仍然很低，最終，醫療服務提供者越來越傾向於選擇更成熟且醫保覆蓋的診斷方案。

肺纖維化生物標記的全球市場趨勢

全球肺纖維化生物標記市場正經歷著向更精準診斷的顯著轉變，其特徵是高通量蛋白質組學和基因組學檢測在臨床應用中的快速普及。這一趨勢的驅動力在於醫療專業人員對這些先進生物標記技術的信心日益增強，這些技術能夠可靠地區分特發性肺纖維化與其他間質性肺部疾病。隨著這些生物標記檢測成為常規患者評估手段，早期診斷將得以實現，從而為患者提供個人化治療方案。診斷公司與專科醫療中心之間的合作正在提高這些檢測的可及性，而關於保險報銷的持續討論也凸顯了其在全球醫療保健系統中實現長期成本效益和改善患者預後的潛力。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球肺纖維化生物標記市場規模：按生物標記類型分類

• 基因生物標記
• 蛋白質生物標記
• 代謝體學物標誌物
• 影像生物標記

全球肺纖維化生物標記市場規模：按樣本類型分類

• 血
• 支氣管肺泡灌洗液
• 肺組織
• 其他生物檢體

全球肺纖維化生物標記市場規模：按應用領域分類

• 診斷
• 預後
• 治療監測
• 藥物發現與開發

全球肺纖維化生物標記市場規模：按最終用戶分類

• 醫院
• 診斷檢查室
• 學術研究機構
• 製藥和生物技術公司

全球肺纖維化生物標記市場規模：按技術分類

• PCR和qPCR
• 次世代定序
• 免疫測量
• 質譜分析

全球肺纖維化生物標記市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Labcorp Holdings Inc.
• Bio-Rad Laboratories, Inc.
• QIAGEN NV
• Bio-Techne Corporation
• Agilent Technologies, Inc.
• Abbott Laboratories
• Danaher Corporation
• PerkinElmer, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.
• SomaLogic Operating Co., Inc.
• Olink Holding AB
• Proteome Sciences plc
• Biodesix, Inc.
• Guardant Health, Inc.
• GRAIL, Inc.
• Genomic Health, Inc.

結論與建議

Global Pulmonary Fibrosis Biomarker Market size was valued at USD 624.0 Million in 2024 and is poised to grow from USD 702.62 Million in 2025 to USD 1815.65 Million by 2033, growing at a CAGR of 12.6% during the forecast period (2026-2033).

The global pulmonary fibrosis biomarker market encompasses assays and imaging agents critical for detecting and monitoring idiopathic pulmonary fibrosis and related interstitial lung diseases. The market's significance is underscored by the disease's high mortality rates and limited treatment options, necessitating effective patient stratification for antifibrotic therapies. Initially dominated by ELISA-based kits targeting surfactant protein-D, recent advancements in next-generation sequencing and proteomics have introduced novel biomarkers like KL-6 and matrix metalloproteinase-7. This innovation is driving commercial launches and fostering partnerships within the industry. Increasing reliance on biomarker data for treatment decisions, alongside rising insurance reimbursement for companion diagnostics and the demand for reliable response markers, is propelling investment and collaboration, significantly enlarging the market's scope and potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pulmonary Fibrosis Biomarker market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pulmonary Fibrosis Biomarker Market Segments Analysis

Global pulmonary fibrosis biomarker market is segmented by biomarker type, sample type, application, end user, technology and region. Based on biomarker type, the market is segmented into Genetic Biomarkers, Protein Biomarkers, Metabolomic Biomarkers and Imaging Biomarkers. Based on sample type, the market is segmented into Blood, Bronchoalveolar Lavage Fluid, Lung Tissue and Other Biological Samples. Based on application, the market is segmented into Diagnosis, Prognosis, Treatment Monitoring and Drug Discovery & Development. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Academic & Research Institutes and Pharmaceutical & Biotechnology Companies. Based on technology, the market is segmented into PCR & qPCR, Next-Generation Sequencing, Immunoassays and Mass Spectrometry. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pulmonary Fibrosis Biomarker Market

The rising emphasis on early detection of pulmonary fibrosis is significantly propelling the global biomarkers market. By enabling clinicians to intervene prior to irreversible tissue changes, there is an increasing demand for sensitive biomarkers capable of identifying the early stages of this disease. Healthcare providers are more focused on proactive disease management, leading them to seek advanced diagnostic tools that facilitate risk assessment and the customization of treatment strategies. This evolving trend fosters a supportive landscape for biomarker developers, encouraging enhanced research investments and the swift development of innovative assays aimed at early therapeutic intervention and better patient outcomes.

Restraints in the Global Pulmonary Fibrosis Biomarker Market

The accessibility of pulmonary fibrosis biomarker tests is hindered by inadequate reimbursement structures within healthcare systems. When insurers offer limited or no coverage, healthcare providers may be reluctant to recommend advanced diagnostic tests due to associated costs for patients, creating a financial barrier. This results in decreased utilization of these tests, which in turn diminishes market demand and disincentivizes manufacturers from increasing production or investing in the development of new assays. As a result, market growth is stunted, with adoption rates remaining low in areas lacking supportive reimbursement policies, ultimately steering providers towards more established and covered diagnostic options.

Market Trends of the Global Pulmonary Fibrosis Biomarker Market

The Global Pulmonary Fibrosis Biomarker market is witnessing a significant shift towards precision diagnostics, marked by the rapid integration of high-throughput proteomic and genomic panels in clinical settings. This trend is propelled by increasing confidence among healthcare providers in these advanced biomarker approaches, which offer a reliable differentiation of idiopathic pulmonary fibrosis from other interstitial lung diseases. As these biomarker suites become routine in patient assessments, they facilitate earlier diagnoses and enable personalized therapy options. Collaborative partnerships between diagnostic companies and specialty medical centers are enhancing assay availability, while ongoing discussions on reimbursement highlight the potential for long-term cost efficiencies and improved patient outcomes within global healthcare systems.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Pulmonary Fibrosis Biomarker Market Size by Biomarker Type & CAGR (2026-2033)

• Market Overview
• Genetic Biomarkers
• Protein Biomarkers
• Metabolomic Biomarkers
• Imaging Biomarkers

Global Pulmonary Fibrosis Biomarker Market Size by Sample Type & CAGR (2026-2033)

• Market Overview
• Blood
• Bronchoalveolar Lavage Fluid
• Lung Tissue
• Other Biological Samples

Global Pulmonary Fibrosis Biomarker Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diagnosis
• Prognosis
• Treatment Monitoring
• Drug Discovery & Development

Global Pulmonary Fibrosis Biomarker Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

Global Pulmonary Fibrosis Biomarker Market Size by Technology & CAGR (2026-2033)

• Market Overview
• PCR & qPCR
• Next-Generation Sequencing
• Immunoassays
• Mass Spectrometry

Global Pulmonary Fibrosis Biomarker Market Size & CAGR (2026-2033)

• North America (Biomarker Type, Sample Type, Application, End User, Technology)
  • US
  • Canada
• Europe (Biomarker Type, Sample Type, Application, End User, Technology)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Biomarker Type, Sample Type, Application, End User, Technology)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Biomarker Type, Sample Type, Application, End User, Technology)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Biomarker Type, Sample Type, Application, End User, Technology)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Holdings Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SomaLogic Operating Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olink Holding AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proteome Sciences plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biodesix, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GRAIL, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations